Search for Clinical Trial Results
Congenital Hyperinsulinism - 18 Studies Found
| Status | Study |
| Completed |
Study Name: A Single-Dose Open-Label Study of XOMA 358 in Subjects With Congenital Hyperinsulinism Condition: Congenital Hyperinsulinism Date: 2015-10-26 Interventions:
|
| Recruiting |
Study Name: Fluorodopa F 18 in Congenital Hyperinsulinism Condition: Congenital Hyperinsulinism Date: 2013-12-20 Interventions: Drug: Fluorodopa F 18 A dose of Fluorodopa F 18, 3-6 MBq/Kg (0.08-0.16 mCi/kg), will be injected intrave |
| Recruiting |
Study Name: Lanreotide Autogel Treatment of Patients With Congenital Hyperinsulinism of Infancy Condition: Congenital Hyperinsulinism Date: 2010-02-17 Interventions: Drug: Lanreotide autogel The dose of Lan-ATG will be calculated according to the surface area of the pat |
| Completed |
Study Name: Effect of Exendin-(9-39) on Glycemic Control in Subjects With Congenital Hyperinsulinism Condition: Congenital Hyperinsulinism Date: 2007-12-10 Interventions:
|
| Completed |
Study Name: Towards Individualized Surgery in Non-focal Congenital Hyperinsulinism Condition: Non-focal Congenital Hyperinsulinism Date: 2014-03-28 Interventions: Procedure: restrictive pancreatic resection Restrictive, spleen-preserving resection of the pancreatic t |
| Recruiting |
Study Name: CSI-Glucagon for Prevention of Hypoglycemia in Children With Congenital Hyperinsulinism Condition: Congenital Hyperinsulinism Date: 2016-10-14 Interventions:
|
| Completed |
Study Name: Effect of Exendin-(9-39) on Fasting Adaptation and Protein Sensitivity Condition: Congenital Hyperinsulinism Date: 2009-05-08 Interventions:
|
| Recruiting |
Study Name: Effect of Exendin-(9-39) On Glucose Requirements To Maintain Euglycemia Condition: Congenital Hyperinsulinism Date: 2009-02-02 Interventions:
|
| Completed |
Study Name: Sandostatine® LP and Hyperinsulinism Condition: Congenital Hyperinsulinism Date: 2009-09-29 Interventions: Drug: Sandostatine LP Intramuscular injection of Sandostatine LP, once per month Dosage : 10 mg, 20 mg, |
| Available |
Study Name: Compassionate Use of SOM230 for Hyperinsulinemic/Hypoglycemia Condition: Congenital Hyperinsulinism Date: 2016-07-13 Interventions: Drug: Pasireotide Other Names:
|